Similar articles

• Regulators adopt more orphan drugs.

  Reardon S. Reardon S. Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a. Nature. 2014. PMID: 24695293 No abstract available.
• Big pharma moves from 'blockbusters' to 'niche busters'.

  Dolgin E. Dolgin E. Nat Med. 2010 Aug;16(8):837. doi: 10.1038/nm0810-837a. Nat Med. 2010. PMID: 20689537 No abstract available.
• [Authorization and reimbursement of orphan drugs in an international comparison].

  Roll K, Stargardt T, Schreyögg J. Roll K, et al. Gesundheitswesen. 2011 Aug;73(8-9):504-14. doi: 10.1055/s-0030-1262864. Epub 2010 Sep 16. Gesundheitswesen. 2011. PMID: 20848380 Review. German.
• New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.

  Lee J. Lee J. Mod Healthc. 2013 Oct 7;43(40):14. Mod Healthc. 2013. PMID: 24340725 No abstract available.
• Rare diseases, orphan drugs and their regulation: questions and misconceptions.

  Tambuyzer E. Tambuyzer E. Nat Rev Drug Discov. 2010 Dec;9(12):921-9. doi: 10.1038/nrd3275. Epub 2010 Nov 9. Nat Rev Drug Discov. 2010. PMID: 21060315 Review.